

# HIV DRUG RESISTANCE REPORT 2019







# **HIV DRUG RESISTANCE REPORT 2019**



**World Health  
Organization**

WHO/CDS/HIV/19.21

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** HIV Drug Resistance Report 2019. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.21). Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

# CONTENTS

Definitions	iv
Acknowledgements	iv
Executive summary	v
Section 1. Pretreatment HIV drug resistance among adults initiating first-line antiretroviral therapy	1
Section 2. Pretreatment HIV drug resistance among treatment-naive infants newly diagnosed with HIV	7
Section 3. Acquired HIV drug resistance among adults receiving antiretroviral therapy	10
Section 4. Assessment of programmatic quality indicators associated with the emergence of HIV drug resistance	16
<b>Tables</b>	
Section 1. Tables of pretreatment HIV drug resistance among adults initiating first-line antiretroviral therapy	19
Population characteristics (Tables 1.1a–e)	19
Prevalence of pretreatment HIV drug resistance (Tables 1.2a–e)	24
Section 2. Tables of pretreatment HIV drug resistance among treatment-naive infants newly diagnosed with HIV	29
Population characteristics (Tables 2.1a–b)	29
Prevalence of pretreatment HIV drug resistance (Tables 2.2a–b)	31
Section 3. Tables of acquired HIV drug resistance among adults receiving antiretroviral therapy	33
Population characteristics (Tables 3.1a–g)	33
Prevalence of viral load suppression (Tables 3.2a–h)	40
Prevalence of acquired HIV drug resistance (Tables 3.3a–h)	40
Table: HIV subtype distribution	56

## DEFINITIONS

**HIV drug resistance (HIVDR)** is caused by one or more changes (mutation/s) in the genetic structure of HIV that affects the ability of a specific drug or combination of drugs to block replication of the virus. All current antiretroviral (ARV) drugs, including newer classes, are at risk of becoming partly or fully inactive because of the emergence of drug-resistant virus. People receiving ART can acquire HIVDR, and people can also be infected with HIV that is already drug resistant. WHO commonly classify HIVDR into three main categories.

1. **Acquired HIV drug resistance (ADR)** develops because of viral replication in the presence of ARV drugs.
2. **Transmitted HIV drug resistance (TDR)** is detected among ARV drug-naïve people with no history of ARV drug exposure. TDR occurs when previously uninfected individuals are infected with virus that has drug resistance mutations.
3. **Pretreatment HIV drug resistance (PDR)** refers to resistance that is detected among ARV drug-naïve people initiating ART or people with previous ARV drug exposure initiating or reinitiating first-line ART. PDR is either TDR or ADR or both. PDR may have been transmitted at the time of infection (TDR) or may be acquired through previous ARV drug exposure (such as among women exposed to ARV drugs for preventing mother-to-child transmission of HIV, among people who have received pre-exposure prophylaxis or among individuals reinitiating first-line ART after a period of treatment interruption).

**ARV drug-naïve** applies to people with no history of ARV drug exposure.

## ACKNOWLEDGEMENTS

The report was written by Seth Inzaule and Silvia Bertagnolio (WHO, HIV Department), under the coordination of Meg Doherty (WHO, HIV Department).

We are extremely grateful for the contributions of Amalia Girón for the statistical analysis. We also thank Neil Parkin, Michael R. Jordan, Natalie Exner and the HIVResNet steering group members for their guidance and support. We acknowledge the contributions of David Breuer for technical editing and Sue Hobbs for layout.

This report would not have been possible without the collaboration of national HIV programme managers who supplied the surveillance data that underpin this report and staff from WHO regional and country offices, especially Fatim Cham, Giovanni Ravasi, Linh Le and B.B.Rewari. We thank the WHO HIVResNet Laboratory Network members, who have been essential in producing high-quality drug resistance surveillance data.

**Financial acknowledgements.** This report has been supported in part by the Government of the Netherlands and the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Centers for Disease Control and Prevention (CDC). We also acknowledge the support of Global Fund and PEPFAR to fund the HIVDR surveys. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funders.

# EXECUTIVE SUMMARY


The rise in antimicrobial resistance (AMR) is one of the greatest threats to global health. If it is not urgently addressed, it may result in millions of deaths, an increase in new and hard-to-treat infections and increased health-care costs.<sup>1</sup> As a result, combatting AMR, including the threat posed by drug-resistant HIV, is a major goal for the global community. Prevention, monitoring and timely response to population levels of HIV drug resistance (HIVDR) is critical to achieving the WHO/UNAIDS 90–90–90 targets for 2020 that 90% of people living with HIV know their HIV status, 90% of those who know their HIV-positive status are accessing treatment and 90% of the people receiving treatment having suppressed viral loads. These targets reflect the global community’s commitment to eliminating AIDS as a public health threat by 2030. In response to the threat of HIVDR to attaining these goals, the global health community launched a five-year Global Action Plan on HIVDR (2017–2021) that details a roadmap to prevent, monitor and respond to globally increasing levels of HIVDR. In response to the Global Action Plan, countries and funders are increasingly focusing on establishing robust and routine population-level monitoring of HIVDR to accompany the scaling up of antiretroviral therapy (ART) and supporting a safe transition to new antiretroviral (ARV) drugs in first- and second-line ART.

Substantial progress has been made in monitoring the population-level emergence and transmission of HIVDR. Between 2004 and 2018, 49 countries implemented surveys of HIVDR using WHO-recommended standard methods. A further 35 countries have plans to conduct surveys (Fig. 1). This report presents findings from 44 nationally representative HIVDR surveys implemented in 24 low- and middle-income countries using WHO standard survey methods.<sup>2</sup>

In 12 of 18 countries reporting survey data to WHO between 2014 and 2018, levels of pretreatment HIVDR (PDR) to efavirenz (EFV) and/or nevirapine (NVP) among adults initiating first-line ART exceeded 10% (Fig. 2). Overall, levels of NNRTI PDR are nearly twice as high among women as among men.

These findings are important, since women comprise a larger proportion of the population living with HIV globally and especially in sub-Saharan Africa, the region with the highest burden of HIV infection. Another subpopulation at high risk of PDR is individuals reinitiating first-line ART and reporting previous exposure to ARV drugs (for example, for preventing the mother-to-child transmission of HIV, previous ART for treating HIV infection, post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP)

**Fig. 1. Implementation of national HIV drug resistance surveys, 2004–2018**



<sup>1</sup> No time to wait: securing the future from drug-resistant infections: report to the Secretary-General of the United Nations. New York: Ad Hoc Interagency Coordination Group on Antimicrobial Resistance; 2019 ([https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG\\_final\\_report\\_EN.pdf?ua=1](https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1), accessed 5 July 2019).

<sup>2</sup> HIV drug resistance surveillance guidance: 2015 update. Geneva: World Health Organization; 2015 ([https://apps.who.int/iris/bitstream/handle/10665/204471/9789241510097\\_eng.pdf;jsessionid=42B6287D67B61D-47BC29C36FD598DAA8?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/204471/9789241510097_eng.pdf;jsessionid=42B6287D67B61D-47BC29C36FD598DAA8?sequence=1), accessed 5 July 2019).

**Fig. 2. NNRTI pretreatment drug resistance in 18 countries reporting national survey data to WHO, 2014–2018**

WHO region	Country	Survey year	Prevalence of NNRTI PDR				
			All (women and men)	Women	Men	ART initiators reporting being ARV drug naive	ART initiators reporting previous ARV drug exposure
African region	Cameroon	2015	<10%	10-30%	<10%	<10%	10-30%
	Eswatini	2016	10-30%	10-30%	<10%	<10%	10-30%
	Namibia	2015	10-30%	10-30%	10-30%	<10%	>30%
	Uganda	2016	10-30%	10-30%	10-30%	10-30%	10-30%
	South Africa	2017	10-30%	10-30%	10-30%		
	Zimbabwe	2015	10-30%	10-30%	<10%	10-30%	
Region of the Americas	Argentina	2014	10-30%	10-30%	10-30%	<10%	10-30%
	Brazil	2014	<10%	<10%	<10%	<10%	
	Colombia	2016	<10%	<10%	<10%	<10%	
	Cuba	2017	10-30%	>30%	10-30%	10-30%	
	Guatemala	2016	10-30%	10-30%	10-30%	10-30%	10-30%
	Honduras	2016	10-30%	>30%	10-30%	10-30%	>30%
	Mexico	2017	<10%	10-30%	<10%	<10%	10-30%
	Nicaragua	2016	10-30%	>30%	10-30%	10-30%	>30%
Western Pacific Region and South-East Asia Region	Myanmar	2016	<10%	<10%	<10%	<10%	10-30%
	Nepal	2016	10-30%	10-30%	10-30%		
	Papua New Guinea	2017	10-30%	10-30%	10-30%	10-30%	>30%
	Viet Nam	2017	<10%	<10%	<10%	<10%	10-30%

Prevalence of PDR to EFV and/or NVP: ■ <10% ■ 10-30% ■ >30%

NNRTI resistance is defined as resistance to NVP or EFV. Previous ARV drug exposure: participants self-reporting being exposed to ARV drugs, such as women exposed to ARV drugs for preventing the mother-to-child transmission of HIV who interrupted ART after delivery and restarted care after a period of time; or defaulters restarting ART. Note that white (empty) cells represent lack of information because surveys excluded people with previous ARV drug exposure (Brazil, Colombia, Cuba and Zimbabwe) or no data on previous exposure were available (Nepal and South Africa).

*Fig. 2. In 12 of 18 countries the NNRTI PDR prevalence had exceeded 10%. Among women, NNRTI PDR was >10% in 14/18 countries, while among men PDR NNRTI prevalence was >10% in 10/18 countries. The NNRTI PDR prevalence among individuals starting first-line ART and reporting previous ARV drug exposure exceeded 10% in all reporting countries.*

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25149](https://www.yunbaogao.cn/report/index/report?reportId=5_25149)

